Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453633 | Lung Cancer | 2018 | 6 Pages |
Abstract
Using a willingness-to-pay threshold of £50,000, pembrolizumab is not cost-effective at its current list price and a discount of 50% or more is required for it to be cost-effective comparing to commonly prescribed chemotherapy. Risk-sharing contracts may be helpful in resolving some of the underlying uncertainty associated with the long-term survival and varying extent of patient response.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xiaohan Hu, Joel W. Hay,